Policy Support for Overdose and access to Naloxone

Mental Health and Substance Abuse Policy
National Department of Health

31 August 2020
Overview of the presentation

- Purpose of the presentation
- Background/Context
- Policy support for overdose and access to Naloxone
Purpose of the presentation

• To present on policy support for overdose and access to Naloxone
UNGASS outcome Document (2016)

Promote the inclusion in national drug policies, in accordance with National legislation and as appropriate, of elements for the prevention and treatment of drug overdose, in particular opioid overdose, including the use of opioid receptor antagonists such as naloxone to reduce drug-related mortality;
Background/Context

The Health Sector Drug Master Plan (HSDMP) 2019-2025

“Increase equitable access to evidence-based, informed HIV-prevention and substance use disorder medications, such as appropriate agonist and partial-agonist therapies and antagonist overdose-reversal medications, at community, primary, secondary and tertiary levels of the public health system.
Naloxone is included in the Standard Treatment Guidelines and Essential Medicines List for South Africa:

- Hospital Level Adults 2019 edition - Chapter 19
- Hospital Level Pediatrics 2017 edition Chapter 18
- Primary Healthcare Level 2018 edition Chapter 21

The documents are available on the website:


Naloxone is included in the draft Opioid Substitution Therapy Implementation Plan And clinical guidelines
Thank You